Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

Published 21/09/2023, 12:51
Updated 21/09/2023, 14:10
© Reuters.  Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

Benzinga - by Lisa Levin, Benzinga Editor.

Gainers

Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.

Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 28.5% to $5.03 in pre-market trading after falling 11% on Wednesday. Neptune Wellness announced intention to spinout Sprout Organics pursuant to the Morgan Stanley agreed to transaction.

Murphy Canyon Acquisition Corp. (NASDAQ: MURF) shares rose 32.4% to $17.00 in pre-market trading. Murphy Canyon Acquisition reported stockholder approval of the proposed combination with Conduit Pharmaceuticals.

TradeUP Acquisition Corp. (NASDAQ: UPTD) shares jumped 24.2% to $15.22 in pre-market trading after surging 26% on Wednesday. The company announced an extension for its initial business combination deadline, depositing an aggregate of $37,432.70 into its trust account.

Alliance Entertainment Holding Corporation (NASDAQ: AENT) shares gained 19.8% to $1.27 in pre-market trading after falling 25% on Wednesday.

Antelope Enterprise Holdings Limited (NASDAQ: AEHL) rose 19.4% to $3.50 in pre-market trading. Antelope Enterprise announced a one-for-ten reverse stock split.

Fresh Vine Wine, Inc. (NYSE: VINE) rose 14.7% to $0.5390 in pre-market trading after gaining over 5% on Wednesday.

MSP Recovery, Inc. (NASDAQ: LIFW) shares surged 14.3% to $0.1758 in pre-market trading after jumping 64% on Wednesday.

Kezar Life Sciences, Inc. (NASDAQ: KZR) gained 13.2% to $1.29 in pre-market trading. Kezar Life Sciences and Everest Medicines collaborated to bring zetomipzomib to patients with lupus nephritis and more across Greater China, South Korea, and Southeast Asia.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Cardiol Therapeutics Inc. (NASDAQ: CRDL) shares climbed 9.1% to $1.08 in pre-market trading.

Losers

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell 16.1% to $0.5540 in pre-market trading after jumping more than 25% on Wednesday.

Akerna Corp. (NASDAQ: KERN) shares fell 13.1% to $0.20 in pre-market trading.

ARB IOT Group Limited (NASDAQ: ARBB) fell 13% to $1.81 in pre-market trading.

Avinger, Inc. (NASDAQ: AVGR) fell 12.2% to $12.11 in pre-market. Avinger said on Sept. 18, 2023, the company increased the amount available for sale by up to an additional aggregate offering price of $2,133,181.

Fitell Corporation (NASDAQ: FTEL) shares fell 11.7% to $2.34 in pre-market trading. Fitell Corporation, last month, announced closing of $15 million initial public offering.

Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares fell 10.8% to $0.34 in pre-market trading after declining around 10% on Wednesday. There were no revenues for the first quarter of fiscal year 2024

Seelos Therapeutics, Inc. (NASDAQ: SEEL) fell 10.1% to $0.2742 in pre-market trading after dipping 69% on Wednesday. Cantor Fitzgerald downgraded Seelos Therapeutics from Overweight to Neutral.

36Kr Holdings Inc. (NASDAQ: KRKR) fell 10% to $0.9001 in pre-market trading after gaining 15% on Wednesday.

Gaucho Group Holdings, Inc. (NASDAQ: VINO) fell 10% to $0.27 in pre-market trading.

Elutia Inc. (NASDAQ: ELUT) fell 9.3% to $1.46 in pre-market trading. The company recently announced a $26 million private placement of 7,355,869 shares of common stock at $1.4275 per share.

Now Read This: FedEx, FactSet Research And 3 Stocks To Watch Heading Into Thursday

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.